Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S009800, C514S177000, C546S210000
Reexamination Certificate
active
08008333
ABSTRACT:
The use of an aromatase inhibitor (AI) in the preparation of a medicament for use in inducing ovulation in a female suffering from anovulatory infertility which comprises administering to said female a single dose of the at least one aromatase inhibitor. The use of an aromatase inhibitor (AI) for the preparation of a medicament comprising a single dose of at least one aromatase inhibitor (AI) for administration to an ovulating female suffering from unexplained infertility or other types of ovulatory infertility early in one or more menstrual cycles. Such a medicament may also be administered to an anovulatory female in combination with a plurality of daily doses of follicle stimulating hormone (FSH) whereby the dosage levels of FSH may be reduced. The use of AI in the preparation of a medicament for administration to a female who is a poor responder to FSH, which comprises a combination of a single dose of AI with a plurality of daily doses of FSH is also disclosed. The related pharmaceutical preparations and packages are also described.
REFERENCES:
patent: 4602025 (1986-07-01), Hirsch et al.
patent: 4728645 (1988-03-01), Browne
patent: 4845227 (1989-07-01), Hirsch et al.
patent: 4916148 (1990-04-01), Edwards et al.
patent: 4978672 (1990-12-01), Bowman et al.
patent: 6015789 (2000-01-01), Suzuki et al.
patent: 6953774 (2005-10-01), Palmer et al.
patent: 43 30 237 (1995-03-01), None
patent: 196 22 457 (1997-11-01), None
Gunapala, et al.; Effect of Estrogen Deprivation on the Reproductive Physiology of Male and Female Primates; 1997; J. Seroid Biochem. Molec. Biol.; vol. 61, No. 3-6, pp. 157-166.
Homburg et al., “Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements.” Human Reproduction Update 1999:5(5);493-499.
Mitwally et al., “High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome.” Human Reproduction 1999:14(11):2700-2703.
Adashi, “Clomiphene Citrate: Mechanism(s) and site(s) of Action—a Hypothesis Revisited,”Fertil Steril, vol. 42, No. 3, pp. 331-344 (1984).
Akhtar et al., “Mechanistic Studies on Aromatase and Related C-C Bond Cleaving P-450 Enzymes,”J. Steroid Biochem Mol Biol, vol. 44, pp. 375-387 (1993).
Archer et al., “Effects of Clomiphene Citrate on Episodic Luteinizing Hormone Secretion Throughout the Menstrual Cycle,”Am J. Obstet Gynecol, vol. 161, No. 3, pp. 581-589 (1989).
Basir et al., “Morphometric Analysis of Peri-Implantation Endometrium in Patients Having Excessively High Oestradiol Concentrations After Ovarian Stimulation,”Hum. Reprod., vol. 16, No. 3, pp. 435-440 (2001).
Bateman et al., “Exogenous Estrogen Therapy for Treatment of Clomiphene Citrate—Induced Cervical Mucus Abnormalities: Is It Effective?”Fertil Steril, vol. 54, pp. 577-579 (1990).
Ben-Ami et al., “Exogenous Estrogen Therapy Concurrent with Clomiphene Citrate—Lack of Effect on Serum Sex Hormone Levels and Endometrial Thickness,”Gynecol Obstet Invest, vol. 37, No. 3, pp. 180-182 (1994)/.
Cole et al., “Mechanism and Inhibition of Cytochrome P-450 Aromatase,”J. Med. Chem., vol. 33, pp. 2933-2944 (1990).
Coombes et al., “4-Hydroxyandrostenedione Treatment of Postmenopausal Patients with Advanced Breast Cancer,”The Lancet 2, pp. 1237-1239 (1984).
Dickey et al., “Observations on the Mechanism of Action of Clomiphene (MRL-41),”Fertil Steril, vol. 16, pp. 485-494 (1965).
Fisch et al., “Unexplained Infertility: Evaluation of Treatment with Clomiphene Citrate and Human Chorionic Gonadotropin,”Fertil Steril, vol. 51, pp. 828-833 (1989).
Fluker et al., “Exogenous Gonadotropin Therapy in World Health Organization Groups I and II Ovulatory Disorders,”Obstet Gynecol, vol. 82, pp. 189-196 (1994).
Forman et al., “Evidence for an Adverse Effect of Elevated Serum Estradiol Concentration on Embryo Implantation,”Fertil Steril, vol. 49, pp. 118-121 (1988).
Garcia et al., “Advanced Endometrial Maturation After Ovulation Induction with Human Menopausal Gonadotropin/Human Chorionic Gonadotropin for In Vitro Fertilization,”Fertil Steril, vol. 41, pp. 31-35 (1984).
Garcia et al., “The Use of Clomiphene Citrate,”Fertil Steril, vol. 28, pp. 707-717 (1997).
Geisler et al., “Influence of Anastrozie (Arimidex), a Selective, Non-Steroidal Aromatase Inhibitor, on In Vitro Aromatisation and Plasma Oestrogen Levels in Postmenopausal Women with Breast Cancer,”Br J Cancer, vol. 74, pp. 1286-1291 (1996).
Gelety et al., “The Effect of Clomiphene Citrate and Menopausal Gonadotropins on Cervical Mucus in Ovulatory Cycles,”Fertil Steril, vol. 60, pp. 471-476 (1993).
Goldfarb et al., “Critical Review of 160 Clomiphene-related Pregnancies,”Obstet Gynecol, vol. 31, pp. 342-345 (1968).
Gonen et al., “Determination of an Adverse Effect of Clomiphene Citrate on Endometrial Growth,”Hum Reprod, vol. 5, pp. 670-674 (1990).
Graf et al., “Histologic Evaluation of the Luteal Phase in Women Following Follicle Aspiration for Oocyte Retrieval,”Fertil Steril, vol. 49, pp. 616-619 (1988).
Hadi et al., “Ovulation Induction and Endometrial Steroid Receptors,”Hum. Reprod., vol. 9, pp. 2405-2410 (1994).
Kettel et al., “Hypothalamic-pituitary-ovarian Response to Clomiphene Citrate in Women with Polycystic Ovary Syndrome,”Fertil Steril, vol. 59, No. 3, pp. 532-538 (1993).
Kolb et al., “Ultrastructural Characteristics of the Luteal Phase Endometrium in Patients Undergoing Controlled Ovarian Stimulation,”Fertil Steril, vol. 67, pp. 625-630 (1997).
Macrow et al., “Endometrial Structure After Superovulation: A Prospective Controlled Study,”Fertil Steril, vol. 61, pp. 696-699 (1994).
Mikkelson et al., “Single-dose Pharmacokinetics of Clomiphene Citrate in Normal Volunteers,”Fertil Steril, vol. 46, pp. 392-396 (1986).
Mitwally et al., “Aromatase Inhibition for Ovarian Stimulation: Future Avenues for Infertility Management,”Current Opinion in Obstetrics&Gynecology, vol. 14 (2002) (Abstract).
Mitwally et al., “Aromatase Inhibition Improves Ovarian Response to Follicle-Stimulating Hormone in Poor Responders,”Fertility&Sterility, vol. 77, pp. 776-780 (2002) (Abstract).
Mitwally et al., “Use of an Aromatase Inhibitor for Induction of Ovulation in Patients with an Inadequate Response to Clomiphene Citrate,”Fertil Steril, vol. 75, No. 2, pp. 305-309 (2001).
Nargund et al., “Cumulative Conception and Live Birth Rates in Natural (unstimulated) IVF Cycles,”Hum. Reprod., vol. 16, pp. 259-262 (2001).
Nebert et al., “The P-450 Superfamily: Update on New Sequences, Gene Mapping and Recommended Nomenclature,”DNA Mol. Biol., vol. 10, pp. 1-14 (1991).
Ng et al., “High Serum Oestradiol Concentration in Fresh IVF Cycles do not Impair Implantation and Pregnancy Rates in Subsequent Frozen-Thawed Embryo Transfer Cycles,”Hum. Reprod., vol. 15, pp. 250-255 (2000).
Noci et al., “Hormonal Patterns, Steroid Receptors and Morphological Pictures of Endometrium in Hyperstimulated IVF Cycles,”Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 75, pp. 215-220 (1997).
Paulson et al., “Factors Affecting Embryo Implantation After Human In Vitro Fertilization: A Hypothesis,”Am J Obstet Gynecol, vol. 163, pp. 2020-2023 (1990).
Randall et al., “Cervical Mucus Score and In Vitro Sperm Mucus Interaction in Spontaneous and Clomiphene Citrate Cycles,”Fertil Steril, vol. 56, pp. 465-468 (1991).
Saleh et al., “Effects of Tamoxifen (Tx) on Endometrial Thickness and Pregnancy Rates in Women Undergoing Superovulation with Clomiphene Citrate (CC) and Intrauterine Insemination (IUI),”Fertil Steril, vol. 74, No. S1, pp. S90 (2000).
Santen et al., “En
Casper Robert F.
Mitwally Mohamed F. M.
Ares Trading S.A.
Krass Frederick
Marshall & Gerstein & Borun LLP
Webb Walter
LandOfFree
Single dose aromatase inhibitor for treating infertility does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Single dose aromatase inhibitor for treating infertility, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Single dose aromatase inhibitor for treating infertility will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670196